Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma

Author： Galsky Matthew   Mironov Svetlana   Iasonos Alexia   Scattergood Joseph   Boyle Mary   Bajorin Dean  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.25, Iss.3, 2007-06, pp. : 265-270

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma

By Li Ning   Ou Wei   Yang Hua   Liu Qian-Wen   Zhang Song-Liang   Wang Bao-Xiao   Wang Si-Yu  

Cancer, Vol. 120, Iss. 9, 2014-05 ,pp. : 1379-1386

Blackwell Publishing

Access to resources Recommend Favorite

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

By Kang Yoon-Koo   Muro Kei   Ryu Min-Hee   Yasui Hirofumi   Nishina Tomohiro   Ryoo Baek-Yeol   Kamiya Yukimasa   Akinaga Shiro   Boku Narikazu  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 355-361

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions

By Lin Nancy   Parker Leroy   Come Steven   Burstein Harold   Haldoupis Margaret   Ryabin Nicole   Gelman Rebecca   Winer Eric   Shulman Lawrence  

Investigational New Drugs, Vol. 25, Iss. 4, 2007-08 ,pp. : 369-375

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma

By Vuky Jacqueline   Isacson Christina   Fotoohi Mehran   Cruz Jason   Otero Henry   Picozzi Vincent   Malpass Thomas   Aboulafia David   Jacobs Andrew  

Investigational New Drugs, Vol. 24, Iss. 1, 2006-01 ,pp. : 85-88

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer

By Caponigro Francesco   Willemse Pax   Sorio Roberto   Floquet Anne   van Belle Simon   Demol Jan   Tambaro Rosa   Comandini Alessandro   Capriati Angela   Adank Sabine   Wanders Jantien  

Investigational New Drugs, Vol. 23, Iss. 1, 2005-01 ,pp. : 85-89

Springer Publishing Company

Access to resources Recommend Favorite